हिंदी खबर

Massachusetts [US], February 14 (ANI): A new clinical study published in The New England Journal of Medicine today and simultaneously presented during the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium claims that a drug combination of Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer.

Read more

more news

iocl